On 17 November 2023, the Commission adopted a new decision with improved rules for refund of expenses for fertility treatments incurred by JSIS beneficiaries. The changes are set out below:

From now on, staff members (or their spouse or registered partner) no longer need to have a fertility issue linked to a pathology for the fertility treatments to be reimbursed by JSIS.

This opens up reimbursement of intra-uterine insemination (IUI) and in vitro fertilisation (IVF) costs for women couples (and single women)!

The Decision however does not cover IVF or IUI costs incurred by non JSIS beneficiaries (meaning costs incurred by a surrogate mother are not covered).

The Decision provides a list of treatments that can be reimbursed, including include pharmaceutical and surgical fertility treatments, such as ovulation induction agents, agents to improve sperm quality, laparoscopy, salpingectomy, myomectomy, and in vitro fertilisation.

There will be no reimbursements for interventions to reverse a voluntary sterilisation or vasectomy.

For IVF, there is now a maximum of eight attempts covered per beneficiary, with the first IVF attempt having to take place before the beneficiary’s 45th birthday.

There is a transition period: treatments incurred in the 18 months prior to the entry into force of the decision are eligible for reimbursement.

The official communication can be found here.